• Acucela and Otsuka Receive FDA Fast Track Designation D...
  From Business Wire
  BOTHELL, Wash. & TOKYO -- Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutic... (Read more)
• Subretinal Implant Restores Unprecedented Level of Visi...
  From Business Wire
  REUTLINGEN, Germany -- Retina Implant, AG, a leading developer of subretinal implants for the visually impaired, today announced scientific revelations discovered during ... (Read more)
• Avedro Becomes Sponsor of US FDA Clinical Trials of Cor...
  From Avedro
  WALTHAM, Mass. -- Avedro, Inc. today announced it has signed a definitive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies... (Read more)
• FDA Warns ISTA Pharmaceuticals Over Sales Ad For Xibrom...
  From Wall Street Journal
  WASHINGTON -- The U.S. Food and Drug Administration said a professional sales ad for ISTA Pharmaceuticals Inc.'s (ISTA) eye solution Xibrom is misleading because it sugge... (Read more)
• Drug Giants Lag Where Sales Boom, Study Says
  From The New York Times
  The leading drug makers need to move quickly to adapt to a new world order in which some emerging markets are set to overtake some established national markets in pharmac... (Read more)

Subscribe to EyewireToday.com